Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance

This publication has 11 references indexed in Scilit:

• HIV Type 1 Diversity in France, 1999–2001: Molecular Characterization of non-B HIV Type 1 Subtypes and Potential Impact on Susceptibility to Antiretroviral Drugs
  AIDS Research and Human Retroviruses, 2003
• Mechanisms of Early Virologic Failure in Antiretroviral?Naive Patients Starting Protease Inhibitor–Containing Regimens: The APROVIR Study
  The Journal of Infectious Diseases, 2002
• Prevalence and clinical correlates of HIV viremia (`blips') in patients with previous suppression below the limits of quantification
  AIDS, 2002
• Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy
  AIDS, 2002
• Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients
  AIDS, 2002
• The natural history and clinical significance of intermittent viraemia in patients with initial viral suppression to < 400 copies/ml
  AIDS, 2002
• Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?
  AIDS, 2002
• The Dynamic of Adherence to Highly Active Antiretroviral Therapy: Results From the French National APROCO Cohort
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
• Transient Relapses (“Blips”) of Plasma HIV RNA Levels During HAART Are Associated With Drug Resistance
  JAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
• Mechanisms of Virologic Failure in Previously Untreated HIV-Infected Patients From a Trial of Induction-Maintenance Therapy
  JAMA, 2000